Medcura Expands Core Team with Regulatory, Manufacturing and Financial Talent

Medcura, a privately held, clinical-stage medical device company, announces the recent expansion of its core team, adding Elsa Abruzzo as Head of Regulatory, Bruce Choi as Head of Manufacturing, and Rich Vincent as the CFO.Supported by its recent financing, the Company has been able to attract an experienced and talented group to support key corporate objectives: expanding Medcura’s initial U.S. FDA regulatory clearance to a broader hemostatic product line for the treatment of external wounds, establishing cGMP manufacturing of Medcura active ingredient, and preparing for the commercialization of its growing product line.“Elsa, Bruce and Rich have already started making contributions as part of our expanded Medcura team,” said Larry Tiffany, President and Director of Medcura “Elsa has been instrumental in designing and implementing our regulatory strategy in order to expand our label claims for a variety of hemostatic products. Integrated into this strategy, Bruce is leading our core team to establish a manufacturing facility using a modular manufacturing approach that will support scale-up while ensuring we meet our quality, productivity and efficiency goals. Rich helped us close the recent equity round, and brings his expertise from many successful West Coast life science start-ups and commercial companies, including raising $650M in private and public financings, most recently for Genoa Pharmaceuticals.” To learn more about each of their backgrounds, please visit our team page.